Covered recipient · General Payments record
HARVEY SEROTA
Allopathic & Osteopathic Physicians Internal Medicine Interventional Cardiology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$52,608.99
220 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $43,325.00 | 25 |
| Consulting Fee | $5,025.00 | 3 |
| Food and Beverage | $4,085.59 | 186 |
| Travel and Lodging | $154.56 | 4 |
| Education | $18.84 | 2 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Esperion Therapeutics, Inc. | $20,143.21 | 44 |
| Janssen Pharmaceuticals, Inc | $17,517.98 | 21 |
| AstraZeneca Pharmaceuticals LP | $7,330.32 | 20 |
| Novo Nordisk Inc | $2,868.11 | 10 |
| CVRx, Inc. | $2,791.16 | 8 |
| Novartis Pharmaceuticals Corporation | $381.90 | 35 |
| Vifor Pharma, Inc. | $246.37 | 18 |
| Amgen Inc. | $211.67 | 7 |
| Merck Sharp & Dohme Corporation | $189.34 | 8 |
| Amarin Pharma Inc. | $160.11 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $145.13 | 9 |
| LivaNova USA, Inc. | $125.31 | 2 |
| SANOFI-AVENTIS U.S. LLC | $121.46 | 7 |
| Bayer HealthCare Pharmaceuticals Inc. | $91.20 | 1 |
| ABIOMED | $84.82 | 1 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $44.53 | 7 |
| E.R. Squibb & Sons, L.L.C. | $32.35 | 2 |
| Lilly USA, LLC | $31.24 | 2 |
| ARBOR PHARMACEUTICALS, INC. | $28.40 | 2 |
| BOSTON SCIENTIFIC CORPORATION | $24.10 | 1 |
| BIOTRONIK INC. | $23.76 | 1 |
| Edwards Lifesciences Corporation | $16.52 | 1 |
Page 3 of 5; records 101–150 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
HARVEY SEROTA
NPI 1346264017 · CMS profile ID 243035
Allopathic & Osteopathic Physicians / Internal Medicine / Interventional Cardiology
SAINT LOUIS, MO
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 5; records 101–150 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1346264017?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- HARVEY SEROTA, NPI 1346264017, CMS profile ID 243035. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346264017?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). HARVEY SEROTA, NPI 1346264017, CMS profile ID 243035. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346264017?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- HARVEY SEROTA, NPI 1346264017, CMS profile ID 243035, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1346264017?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
220 matching records · $52,608.99 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 220.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Vifor Pharma, Inc. | $0.32 | 07/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 816117537 | CMS |
| Novartis Pharmaceuticals Corporation | $12.50 | 07/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813245757 | CMS |
| Vifor Pharma, Inc. | $15.28 | 07/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 816117415 | CMS |
| SANOFI-AVENTIS U.S. LLC | $17.50 | 07/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843449081 | CMS |
| Vifor Pharma, Inc. | $17.82 | 07/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 816116681 | CMS |
| Novartis Pharmaceuticals Corporation | $0.71 | 07/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813245745 | CMS |
| Merck Sharp & Dohme Corporation | $13.08 | 07/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848459931 | CMS |
| Novartis Pharmaceuticals Corporation | $13.95 | 06/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813245753 | CMS |
| CVRx, Inc. | $19.95 | 06/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851087217 | CMS |
| Esperion Therapeutics, Inc. | $1,500.00 | 06/23/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838400061 | CMS |
| Esperion Therapeutics, Inc. | $1,500.00 | 06/23/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838400067 | CMS |
| Amarin Pharma Inc. | $15.76 | 06/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815157825 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.20 | 06/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829697485 | CMS |
| Janssen Pharmaceuticals, Inc | $1,000.00 | 06/18/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788135405 | CMS |
| Novartis Pharmaceuticals Corporation | $0.37 | 06/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813245737 | CMS |
| Novartis Pharmaceuticals Corporation | $10.11 | 06/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813245741 | CMS |
| Esperion Therapeutics, Inc. | $14.48 | 06/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838400051 | CMS |
| Esperion Therapeutics, Inc. | $1.89 | 06/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838400053 | CMS |
| Esperion Therapeutics, Inc. | $1,500.00 | 06/16/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838400059 | CMS |
| Novartis Pharmaceuticals Corporation | $17.21 | 06/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813245749 | CMS |
| Amgen Inc. | $19.54 | 06/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825347913 | CMS |
| Novo Nordisk Inc | $22.05 | 06/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 810934539 | CMS |
| BOSTON SCIENTIFIC CORPORATION | $24.10 | 06/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 777716127 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.31 | 06/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829472835 | CMS |
| Esperion Therapeutics, Inc. | $1,500.00 | 06/09/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838400045 | CMS |
| Amarin Pharma Inc. | $9.94 | 06/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815157823 | CMS |
| Vifor Pharma, Inc. | $2.36 | 06/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 816112011 | CMS |
| CVRx, Inc. | $18.01 | 05/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851087215 | CMS |
| ARBOR PHARMACEUTICALS, INC. | $14.21 | 05/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830931455 | CMS |
| Esperion Therapeutics, Inc. | $5.18 | 05/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838400035 | CMS |
| Esperion Therapeutics, Inc. | $1,500.00 | 05/26/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838400037 | CMS |
| Esperion Therapeutics, Inc. | $1,500.00 | 05/26/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838400043 | CMS |
| Merck Sharp & Dohme Corporation | $23.53 | 05/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848542429 | CMS |
| Novartis Pharmaceuticals Corporation | $1.33 | 05/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813245729 | CMS |
| Amgen Inc. | $114.39 | 05/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825347917 | CMS |
| Merck Sharp & Dohme Corporation | $18.01 | 05/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848675515 | CMS |
| Vifor Pharma, Inc. | $16.64 | 05/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 816109083 | CMS |
| Janssen Pharmaceuticals, Inc | $11.38 | 05/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788135433 | CMS |
| Novartis Pharmaceuticals Corporation | $15.90 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813245733 | CMS |
| Novartis Pharmaceuticals Corporation | $13.32 | 05/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813245725 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.96 | 05/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829270843 | CMS |
| AstraZeneca Pharmaceuticals LP | $11.19 | 05/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829890591 | CMS |
| Esperion Therapeutics, Inc. | $10.96 | 05/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838400027 | CMS |
| Esperion Therapeutics, Inc. | $1,500.00 | 05/12/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838400029 | CMS |
| Esperion Therapeutics, Inc. | $3.12 | 05/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838400021 | CMS |
| SANOFI-AVENTIS U.S. LLC | $18.79 | 05/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843449073 | CMS |
| Vifor Pharma, Inc. | $15.13 | 05/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 816106575 | CMS |
| Janssen Pharmaceuticals, Inc | $1,000.00 | 05/03/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788135403 | CMS |
| Janssen Pharmaceuticals, Inc | $1,000.00 | 05/03/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788135407 | CMS |
| Novo Nordisk Inc | $17.23 | 04/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 810771709 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $2,710.63 | 1 |
| PY2025 | Principal investigator | $825,669.99 | 278 |
| PY2024 | Recipient | $960.67 | 1 |
| PY2024 | Principal investigator | $855,022.55 | 15 |
| PY2023 | Recipient | $5,091.38 | 1 |
| PY2023 | Principal investigator | $802,872.17 | 32 |
| PY2022 | Recipient | $45,680.08 | 5 |
| PY2022 | Principal investigator | $881,871.06 | 114 |
| PY2021 | Recipient | $18,810.34 | 7 |
| PY2021 | Principal investigator | $358,058.54 | 491 |
| PY2020 | Principal investigator | $1,010,996.63 | 1,139 |
| PY2019 | Principal investigator | $1,602,601.88 | 621 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
279 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $54.00 | 12/30/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220669344 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $21.75 | 12/30/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220669346 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.35 | 12/30/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220669348 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 12/17/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220995954 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $10,015.45 | 12/17/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220995984 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.00 | 12/15/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669782 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.00 | 12/15/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669784 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $475.00 | 12/15/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669786 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,982.00 | 12/15/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669788 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.00 | 12/15/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669790 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,729.00 | 12/15/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669792 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.00 | 12/15/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669794 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $475.00 | 12/15/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669796 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,909.00 | 12/15/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669798 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,909.00 | 12/15/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669800 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 12/15/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669802 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 12/15/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669804 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 12/15/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669806 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $475.00 | 12/15/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669808 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 12/15/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669810 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 12/15/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669812 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,556.00 | 12/15/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669814 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,556.00 | 12/15/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669816 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,510.00 | 12/15/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669818 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,814.00 | 12/15/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669820 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,510.00 | 12/15/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669822 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $10,015.45 | 12/12/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220995986 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,598.00 | 12/01/2025 | Non-covered Recipient Entity St. Louis Heart and Vascular | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215507958 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $6,000.00 | 12/01/2025 | Non-covered Recipient Entity St. Louis Heart and Vascular | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215507963 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220669360 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 12/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669778 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 12/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669780 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $475.00 | 11/19/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669758 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,909.00 | 11/19/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669760 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,400.00 | 11/19/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669762 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,400.00 | 11/19/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669764 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 11/19/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669766 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,211.00 | 11/19/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669768 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $475.00 | 11/19/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669770 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,211.00 | 11/19/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669772 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,211.00 | 11/19/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669774 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,510.00 | 11/19/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669776 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $5,007.72 | 11/11/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220995980 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,338.48 | 11/11/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220995982 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220669358 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 11/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669754 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 11/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669756 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.74 | 10/27/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220669362 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 10/27/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220669364 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 10/27/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669824 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.22 | 10/27/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669826 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $21.00 | 10/27/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669828 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.82 | 10/27/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669830 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $56,183.92 | 10/22/2025 | Non-covered Recipient Entity ST LOUIS HEART AND VASCULAR PC | a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure | No dispute reported | 06/30/2026 | 1185555593 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $10,015.45 | 10/21/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220995978 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,982.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669700 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $475.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669702 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,556.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669704 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,556.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669706 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,510.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669708 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,556.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669710 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,909.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669712 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669714 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,814.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669716 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,814.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669718 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,510.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669720 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,909.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669722 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,211.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669724 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669726 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669728 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,211.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669730 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,211.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669732 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,774.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669734 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,211.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669736 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669738 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $475.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669740 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669742 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669744 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669746 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,211.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669748 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669750 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 10/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669752 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $23,081.00 | 10/17/2025 | Non-covered Recipient Entity Saint Louis Heart And Vascular, PC | Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) (AURORA-HFpEF) | No dispute reported | 06/30/2026 | 1235994099 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $9,300.00 | 10/02/2025 | Non-covered Recipient Entity ST LOUIS HEART AND VASCULAR PC | A Phase IIb Randomised, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety and Tolerability of Coadministration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight with Co-morbidity (ASCEND) | No dispute reported | 06/30/2026 | 1185555603 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220669350 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 10/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220669352 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.75 | 10/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220669354 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 10/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220669356 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 10/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669696 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 10/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669698 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $179.82 | 09/24/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669690 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $401.50 | 09/24/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669692 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.46 | 09/24/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669694 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $13,353.92 | 09/18/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220995976 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $13,042.00 | 09/03/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Pc | BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic | No dispute reported | 06/30/2026 | 1225409082 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 09/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669584 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 09/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669586 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $119.88 | 08/26/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669684 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 08/26/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669686 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.76 | 08/26/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669688 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $30,046.33 | 08/26/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220995974 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,909.00 | 08/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669604 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 08/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669606 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 08/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669608 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 08/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669610 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,556.00 | 08/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669612 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,814.00 | 08/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669614 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,510.00 | 08/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669616 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,814.00 | 08/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669618 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669592 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,510.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669594 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,814.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669596 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,510.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669598 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,909.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669600 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,729.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669602 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,729.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669620 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,556.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669622 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,814.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669624 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,556.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669626 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,510.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669628 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,814.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669630 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,909.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669632 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,814.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669634 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,556.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669636 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,510.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669638 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,814.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669640 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,556.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669642 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,510.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669644 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,814.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669646 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,556.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669648 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,510.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669650 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,909.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669652 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,909.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669654 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669656 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669658 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,556.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669660 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669662 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,556.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669664 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,814.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669666 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,556.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669668 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,814.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669670 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,556.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669672 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,814.00 | 08/13/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669674 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 08/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669580 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 08/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669582 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $159.84 | 07/28/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669676 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $365.00 | 07/28/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669678 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.70 | 07/28/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669680 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.40 | 07/28/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669682 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,982.00 | 07/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669562 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,437.00 | 07/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669564 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,298.00 | 07/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669566 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,298.00 | 07/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669568 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,211.00 | 07/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669570 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,751.00 | 07/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669572 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $475.00 | 07/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669574 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $217.00 | 07/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669576 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $189.00 | 07/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669578 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 07/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669588 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 07/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669590 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 06/24/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220669338 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.98 | 06/24/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220669340 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $359.64 | 06/24/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220669342 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $93.28 | 06/24/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669552 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $319.68 | 06/24/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669554 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $474.50 | 06/24/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669556 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.31 | 06/24/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669558 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.46 | 06/24/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669560 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,211.00 | 06/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669530 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,298.00 | 06/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669532 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,298.00 | 06/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669534 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,298.00 | 06/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669536 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,298.00 | 06/20/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669538 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,513.26 | 06/11/2025 | Non-covered Recipient Entity ST LOUIS HEART AND VASCULAR PC | A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus | No dispute reported | 06/30/2026 | 1185555599 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,982.00 | 06/04/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669494 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,298.00 | 06/04/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669496 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,751.00 | 06/04/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669498 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $155.00 | 06/04/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669500 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,751.00 | 06/04/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669502 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,751.00 | 06/04/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669504 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,751.00 | 06/04/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669506 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,437.00 | 06/04/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669508 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $217.00 | 06/04/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669510 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,437.00 | 06/04/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669512 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,270.00 | 06/04/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669514 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,982.00 | 06/04/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669516 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,982.00 | 06/04/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669518 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,270.00 | 06/04/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669520 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,211.00 | 06/04/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669522 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $217.00 | 06/04/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669524 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $217.00 | 06/04/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669526 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,298.00 | 06/04/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669528 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 06/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669490 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 06/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669492 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $8,346.20 | 05/29/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220995968 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 05/28/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | Ph III HFrEF study | No dispute reported | 06/30/2026 | 1220995952 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $299.70 | 05/27/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669550 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 05/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669486 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 05/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669488 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $20,030.88 | 05/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220995966 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,982.00 | 04/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669448 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $189.00 | 04/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669450 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,751.00 | 04/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669452 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,982.00 | 04/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669454 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,751.00 | 04/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669456 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,437.00 | 04/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669458 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,751.00 | 04/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669460 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,437.00 | 04/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669462 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,437.00 | 04/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669464 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,437.00 | 04/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669466 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,437.00 | 04/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669468 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,982.00 | 04/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669470 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,982.00 | 04/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669472 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,982.00 | 04/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669474 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,982.00 | 04/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669476 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $475.00 | 04/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669478 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,982.00 | 04/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669480 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,298.00 | 04/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669482 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,751.00 | 04/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669484 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $239.76 | 04/23/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669540 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 04/23/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669542 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.74 | 04/23/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669544 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.65 | 04/23/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669546 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.64 | 04/23/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669548 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,996.52 | 04/23/2025 | Non-covered Recipient Entity Saint Louis Heart And Vascular, PC | Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) (AURORA-HFpEF) | No dispute reported | 06/30/2026 | 1235994097 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $5,007.72 | 04/08/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220995970 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $11,684.68 | 04/02/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220995972 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 04/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669444 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 04/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669446 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $519.48 | 03/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669436 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $328.50 | 03/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669438 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $21.00 | 03/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669440 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.58 | 03/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669442 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $5,007.72 | 03/21/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220995964 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,982.00 | 03/19/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669400 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,982.00 | 03/19/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669402 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,982.00 | 03/19/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669404 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,982.00 | 03/19/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669406 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $217.00 | 03/19/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669408 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,298.00 | 03/19/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669410 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,751.00 | 03/19/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669412 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,751.00 | 03/19/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669414 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,437.00 | 03/19/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669416 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,437.00 | 03/19/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669418 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,437.00 | 03/19/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669420 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $11,684.68 | 03/11/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220995962 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 03/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669394 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 03/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669396 |
| Principal investigator 1 | AstraZeneca UK Limited | $152,173.96 | 02/27/2025 | Non-covered Recipient Entity ST LOUIS HEART AND VASCULAR PC | A Phase 2b Randomised,Double blind,Placebo controlled,Multi centre,Dose ranging Study of AZD3427 in Participants with Heart Failure and Pulmonary Hypertension due to Left Heart Disease WHO Group 2 | No dispute reported | 06/30/2026 | 1185555595 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,982.00 | 02/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669378 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,982.00 | 02/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669380 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,982.00 | 02/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669382 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,298.00 | 02/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669384 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,437.00 | 02/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669386 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,437.00 | 02/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669388 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $79.92 | 02/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669432 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.60 | 02/25/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669434 |
| Recipient | Novartis Pharmaceuticals Corporation | $2,710.63 | 02/04/2025 | Covered Recipient Physician | Research Publication/Writing Support | No dispute reported | 06/30/2026 | 1190293594 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 02/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669390 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 02/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669392 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $210.00 | 01/31/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669398 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,669.24 | 01/31/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220995960 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $13,039.10 | 01/29/2025 | Non-covered Recipient Entity ST LOUIS HEART AND VASCULAR PC | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185555601 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,669.24 | 01/29/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220995956 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,338.48 | 01/29/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220995958 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $159.84 | 01/27/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669422 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $438.00 | 01/27/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669424 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.96 | 01/27/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669426 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.50 | 01/27/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669428 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.28 | 01/27/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669430 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,751.00 | 01/24/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669372 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $5,540.66 | 01/22/2025 | Non-covered Recipient Entity ST LOUIS HEART AND VASCULAR PC | This is a randomised double blind placebo controlled multi center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fractio | No dispute reported | 06/30/2026 | 1185555605 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $475.00 | 01/22/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669366 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,298.00 | 01/22/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669368 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,751.00 | 01/22/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669370 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $24,406.43 | 01/08/2025 | Non-covered Recipient Entity ST LOUIS HEART AND VASCULAR PC | a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure | No dispute reported | 06/30/2026 | 1185555597 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 01/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669374 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 01/01/2025 | Non-covered Recipient Entity St Louis Heart And Vascular Cardiology-Christian Hospital Office | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220669376 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $20,096.15 | 01/01/2025 | Non-covered Recipient Entity ST. LOUIS HEART AND VASCULAR P.C. | A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease | No dispute reported | 06/30/2026 | 1214125272 |